Hey Mate,
Novo Nordisk is a huge company.
Novo Nordisk employs more than 48,000 people globally and markets its products in 168 countries.[2] The corporation was created in 1989 through a merger of two Danish companies which dates back to the 1920s.
Its focus is on Diabetes v's Cannvalate being mostly into Cannabis
BUT Novo Nordisk has been interested in Chronic Inflammatory Diseases such as rheumatoid arthritis in past years.
Its Research Focus
Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and
chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies [34] I
n September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.[35]In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on “transformational biological and technological innovation”.[36]
https://en.wikipedia.org/wiki/Novo_Nordisk#DiabetesMaybe Novo's interest in this area of research into rheumatoid arthritis has resurfaced?? (Pure Speculation)
Good luck
@retireearly54